



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 12 April 2018 (#11)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Confirm your intent to apply ASAP, but not later than 30 days before the submission date.

Contact: RGMO Pre-Awards cdevries@sun.ac.za

Important notices:

- **NIH Dissemination Plan Does Not Equal Resource Sharing Plan** As part of your grant application, you must submit a plan for disseminating NIH-funded clinical trial information that addresses how you will meet the expectations of the NIH Policy on the Dissemination of NIH-Funded Clinical Trial Information.
- Notice of National Institute of Neurological Disorders and Stroke (NINDS) **Policy for Submission of Applications Containing Clinical Trials** ([NOT-NS-18-054](#))
- Notice of Intent to Publish a Funding Opportunity Announcement for the Reissue of PA-18-568 **International Research Collaboration on Drug Abuse and Addiction Research** (R01 Clinical Trial Optional) ([NOT-DA-18-010](#))
- National Institute of Dental and Craniofacial Research (NIDCR) Policy on Applications for Investigator-Initiated Clinical Trials ([NOT-DE-18-014](#))
- National Institute of Neurological Disorders and Stroke (NINDS) Notice of Policy for Submission of Applications Containing Clinical Trials ([NOT-NS-18-054](#))

1. African Postdoctoral Training Initiative (APTI)

Applications open: 11 April, 2018

Application deadline: 11 May 11 2018

Final selection: 1 June 2018

Beginning of fellowship at NIH: no later than 30 September, 2018.

Funding Opportunity Announcement: The African Academy of Sciences (AAS), the U.S. National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation are partnering under the auspices of the Coalition of African Research & Innovation (CARI) to establish a post-doctoral training fellowship program, the [African Postdoctoral Training Initiative \(APTI\)](#). The main objective of APTI is to train a cadre of African scientists so they return to their home institutions and become scientific leaders in their community, help solve Africa's challenges in global health and development, and in turn become trainers of the next generation. The research priority areas are in infectious diseases, nutrition, and reproductive, maternal, and child health and developing skills for clinical and translational research.

Training will be at a world class institute, the intramural laboratories of NIH. While at the NIH, the fellows must be on leave or sabbatical from their home institution under the NIH Intramural Visiting Fellow Program. APTI fellows will be expected to lead important research programs in their home countries and institutions. After successful completion of the two-year postdoctoral fellowship, trainees will be provided with 50% salary support for an additional two years to assist their transition into independent researchers.

Candidate requirements:

- Must be citizens of and currently employed in an academic, research, or government position in an African country.
- Must have a relevant doctoral degree (e.g., PhD, MD, MBBS) awarded no more than 15 years earlier.
- Must have less than 5 years of relevant research experience by their entry on duty date at NIH.

Selection criteria:

- Professional merit, scientific ability, and potential future career impact (based on CV, letter of interest, and two reference letters).
- Assurance and availability of resources from the home institution for a designated, funded research position for the postdoc upon completion of their fellowship (expressed in letter from director/head of research of home institution).
- Commitment to return to their home country following completion of training (expressed in a letter of interest).
- A selection committee will ensure the best match of outstanding candidates and NIH laboratory positions. Additional selection factors may include diversity in scientific research areas, geographic origin, and gender

Enquiries:

- **Grants Officer, African Academy of Sciences:** Susan Gichoga, Phone: +254 20 240 5150. Email: apti@aacsciences.ac.ke
- **Program Specialist, Fogarty International Center, NIH:** Jackie Officer, Phone: +1-301-496-4784. Email: jackie.officer@nih.gov
- **Program Officer, Fogarty International Center, NIH:** Stacy Wallick, Phone: +1-301-496-4784. Email: stacy.wallick@nih.gov

2. National Institutes of Health (NIH) Office of AIDS Research (OAR) Training Fellowship Awards

Hyperlink: [OAR HIV 2018](#)

Type: *Fellowship*

Applications open: 2 April 2018

Application Deadline: 30 May 2018

All activity must be completed by: 30 September 2019.

Funding Opportunity Announcement: CRDF Global is accepting proposals from early-stage investigators working in the field of HIV research for the U.S. National Institutes of Health (NIH) Office of AIDS Research (OAR) Training Fellowship Awards, 2018. This initiative is funded by CRDF Global [utilizing funds provided by OAR through the National Institute of Allergy and Infectious Diseases (NIAID)]. The fellowship program aims to promote the training and inclusion of early-stage scientists in HIV-related collaborative research. It represents the first round of a research training program, building upon ongoing collaborations in HIV research that are co-funded by OAR/NIH and its counterpart funding agencies in countries participating in the NIH bilateral collaborative research programs over the past ten years. The purpose of the award is to expand capacity in HIV research through participation in short-term research training opportunities for early-stage investigators affiliated with institutions engaged in the bilateral collaborative research programs, which include HIV-related research co-funded by OAR and the counterpart funding agencies in Brazil, China, India, Russia, and South Africa. Investigators from these countries and the U.S. are invited to apply for funding for research training projects, focused on priority areas of HIV research listed below:

- Reduce HIV incidence
- Develop next generation HIV therapies
- Research toward HIV cure
- Address HIV-associated comorbidities, coinfections, and complications
- Cross-cutting research (including basic research, behavioral and social science research, research in health disparities, information dissemination)

Each applicant must:

- Applicants must be U.S. or foreign nationals from Brazil, China, India, Russia, and South Africa
- Have completed a Ph.D., M.D., or other equivalent graduate or professional degree within the past 10 years.
- Demonstrate scientific capacity and relevant research experience.

Individuals who serve as Principal Investigators (PI) on an NIH Office of AIDS Research (OAR)-supported HIV collaborative research award through one of the NIH bilateral programs **are not** eligible to apply.

Applicants may identify scientists employed by the U.S. Federal government (e.g. NIH) as mentors for the training; however the U.S. PI and affiliated Federal agency are not permitted to receive funding under this Award Program.

Budget: Budget allocation must total 100% and may not exceed \$25,000 USD. Funds must be used to cover only travel/living expenses and training costs, including registration fees for training courses. The institution hosting the training is expected to provide a sufficient level of in-kind support (i.e. cost-sharing) to facilitate the trainer/trainee's visit, but limited funds (not to exceed \$5,000 USD) may be requested by the institution hosting the training to cover costs that directly support the identified training (e.g. reagents, instrumentation, venue and A/V costs, training supplies, etc.). These funds must be included in the applicant's budget and referenced in the host/mentor's letter of support.

3. Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (Clinical Trial Optional).

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-18-738\)](#)
[\(PA-18-739\)](#)

Type: *R01*
R21

Application Due Date: [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The overall purpose of this funding opportunity announcement (FOA) is to assess the role of the microbiome in health and disease during aging. This initiative will support research projects designed to evaluate changes in the microbiota during lifetime and its influence in health and disease status in the elderly, including those from racial/ethnic minority and underserved populations and understand the underlying mechanisms of microbiota interactions in aged subjects as related to health and disease. This FOA will support basic mechanistic, preclinical studies in animal models and human clinical trial proposals in accordance with the state of the science.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The project period may not exceed 5 years.

4. Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-18-741\)](#)

Type: *R21*

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushing's diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and nutrition; kidney, urologic, and hematologic diseases. The goal of this program is to facilitate research that explores innovative hypotheses through the use of existing data sets or data, for which the primary goal is data analysis and not preparation/presentation of data.

Budget: Direct costs are limited to \$275,000 over a two-year period, with no more than \$200,000 in direct costs allowed in any single year. Application budgets need to reflect the actual needs of the proposed project.

5. Investigator-Initiated Genomic Medicine Research (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-18-735\)](#)
[\(PAR-18-736\)](#)

Type: R01
R21

Application Due Date: June 20, 2018; October 19, 2018; June 20, 2019; October 21, 2019; June 19, 2020; October 20, 2020 and **Aids dates:** September 20, 2018; January 22, 2019; September 23, 2019; January 22, 2020; September 21, 2020; January 22, 2021 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This opportunity supports research opportunities that will advance our understanding of, and the implementation of, the use of genomic information about an individual to inform clinical care, and the health outcomes of that clinical use.

Budget: R01 - Application budgets should reflect the actual needs of the proposed project, and must be under \$500,000 direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 4 years.

R21 - Application budgets should reflect the actual needs of the proposed project. The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

6. Exploring Epigenomic or Non-Coding RNA Regulation in the Development, Maintenance, or Treatment of Chronic Pain (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-18-742\)](#)

Type: R61/R33

Application Due Date: July 17, 2018, November 13, 2018 February 11, 2019, July 17, 2019, November 13, 2019, February 11, 2020, July 17, 2020, November 13, 2020, February 11, 2021. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this initiative is to encourage research that investigates the role of epigenetic or non-coding RNA regulatory pathways in the development, maintenance, or treatment of chronic pain. Ultimately research in the area will provide foundational knowledge that can be exploited to develop novel and non-addictive pain medications or to develop biomarkers that predict chronic pain progression or treatment response.

Budget: Application budgets are limited to direct costs of \$300k/year for each year of the R61 phase and \$450k/year for each year of the R33 phase. The budget request should reflect the actual needs of the proposed project. Application budgets are limited in time to a maximum of two years for the R61 phase and a maximum of three years for the R33 phase.

7. Pilot and Feasibility Clinical Research Grants in Urologic Disorders (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-18-743\)](#)

Type: R21

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) is to support Exploratory/Developmental Research Grants (R21) that propose small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to urologic disorders research. Studies should address important clinical and translational questions that are potentially of high clinical and public health impact. It is anticipated that some projects supported by these grants may lead to full-scale clinical studies including diagnostic strategies, epidemiological studies, or randomized clinical trials of prevention, diagnosis or treatment of urologic disorders.

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

8. Pilot and Feasibility Clinical Research Grants in Kidney Diseases (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-18-744\)](#)

Type: R21

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) is to support Exploratory/Developmental Research Grants (R21) that propose small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to kidney disease research. Studies should address important clinical and translational questions and are potentially of high clinical and public health impact. It is anticipated that some projects supported by these grants may lead to full-scale clinical studies including diagnostic strategies, epidemiological studies, or randomized clinical trials of diagnosis, prevention, or treatment of kidney diseases.

Budget: Direct costs are limited to \$275,000 over the two-year period. No more than \$200,000 in direct costs may be requested in any single year. Application budgets should reflect the actual needs of the proposed project.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)